Expected R&D milestones

Pipeline charts as communicated at Q4 and Full Year 2019 Results Meeting dated February 6, 2020

Products	Expected milestones	Timing
cemiplimab(1)(**)	Pivotal trial read-out in 2L Basal Cell Carcinoma	**H1 2020**
Sarclisa®	U.S. and EU regulatory decisions in 3L Relapsed-Refractory Multiple Myeloma	**Q2 2020**
Dupixent®(1)(**)	U.S. regulatory decision in Atopic Dermatitis for 6-11 year-old age group(2)	**Q2 2020**
MenQuadfi™	U.S. regulatory decision for ≥ 2-year old age group	**Q2 2020**
Fluzone® QIV HD	EU regulatory decision for ≥ 65-year old age group	**Q2 2020**
avalglucosidase alfa	Pivotal trial read-out in Late Onset Pompe Disease	**Q2 2020**
isatuximab	Pivotal trial read-out in 2L Relapsed-Refractory Multiple Myeloma (IKEMA)	**Q2 2020**
Dupixent®(1)(**)	Part A readout from pivotal trial in Eosinophilic Esophagitis	**Q2 – Q3 2020**
sutimlimab	U.S. regulatory decision in Cold Agglutinin Disease	**Q3 2020**
SAR440340(1)(**) (anti-IL33 mAb)	Proof of concept study read-out in Atopic Dermatitis	**Q3 2020**
SAR439859 (SERD)	Proof of concept study read-out in Breast Cancer (combo, adj.)	**H2 2020**
Flublok®	EU regulatory decision for ≥ 50-year old age group	**Q4 2020**
MenQuadfi™	EU regulatory decision for ≥ 12-month old age group	**Q4 2020**
Dupixent®(1)(**)	Pivotal trial read-out in Asthma for 6-11 year old age group	**Q4 2020**

(1) Developed in collaboration with Regeneron
(2) Granted breakthrough designation and priority review with FDA Decision May 26,2020
(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products
QIV: Quadrivalent Influenza Vaccine; HD: High-Dose

SANOFI